MARKET

AGLE

AGLE

Aeglea Bio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.39
-0.25
-3.27%
After Hours: 7.39 0 0.00% 16:00 01/24 EST
OPEN
7.68
PREV CLOSE
7.64
HIGH
7.68
LOW
7.33
VOLUME
48.95K
TURNOVER
--
52 WEEK HIGH
9.45
52 WEEK LOW
5.99
MARKET CAP
214.20M
P/E (TTM)
-3.0566
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of AGLE and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

AGLE News

  • Aeglea BioTherapeutics Submits CTA Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)
  • GlobeNewswire.01/13 12:00
  • Is Aeglea BioTherapeutics, Inc.'s (NASDAQ:AGLE) CEO Salary Justified?
  • Simply Wall St..01/08 10:11
  • Aeglea BioTherapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference
  • GlobeNewswire.01/06 21:05
  • Hedge Funds Are Dumping Aeglea BioTherapeutics, Inc. (AGLE)
  • Insider Monkey.12/13/2019 00:08

More

Industry

Biotechnology & Medical Research
-2.64%
Pharmaceuticals & Medical Research
-2.00%

Hot Stocks

Name
Price
%Change

About AGLE

Aeglea BioTherapeutics, Inc. is a biotechnology company engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. Its lead product candidate, pegzilarginase, is engineered to degrade the amino acid arginine and is being developed to lower arginine levels in patients with Arginase I Deficiency. Its AEB4104 product candidate is a recombinant human enzyme that degrades the amino acid homocysteine and its oxidized form homocystine. It is developing AEB4104 for the treatment of patients with cystathionine beta synthase (CBS) deficiency. Its AEB5100 products candidate is a recombinant human enzyme that degrades plasma cystine and cysteine. It is developing AEB5100 product candidate for the treatment of patients with cystinuria. Its AEB3103 product candidate is an engineered human enzyme that targets the degradation of the amino acid cysteine/cystine.
More

Webull offers Aeglea Bio Therapeutics Inc (AGLE) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.